Beam Therapeutics reports pivotal trial success for risto‑cel but shares tumble
Beam Therapeutics announced that its BEACON Phase 1/2 trial of the base‑editing therapy risto‑cel met its primary efficacy endpoint, with 31 patients remaining free from severe vaso‑occlusive crises for at least 12 months. The company said 49 patients had been treated as of the October 2026 data cutoff and plans to file a Biologics License Application with the FDA by year‑end 2026. Despite the positive data, Beam’s stock fell more than 10% in trading after the announcement.
Why it matters
The trial outcome positions risto‑cel as a potential first‑to‑market base‑editing therapy, which could drive future revenue if approved, but the immediate share decline (over 10%) reflects market skepticism about commercialization timing and competition.
Key facts
- 1The BEACON trial met its primary efficacy endpoint of freedom from severe vaso‑occlusive crises for at least 12 months. rttnews.com
- 231 patients had completed the required 12‑month follow‑up as of the October 2026 data cutoff. rttnews.com
- 3A total of 49 patients (39 adults and 10 adolescents) had received risto‑cel treatment by the October 2026 cutoff. rttnews.com
- 4Beam plans to submit a Biologics License Application to the FDA as early as year‑end 2026. rttnews.com
- 5Beam’s shares fell more than 10% in Tuesday trading following the announcement. seekingalpha.com
- 6Beam’s shares also fell up to 10% in morning trading, despite the positive trial outcome. finance.yahoo.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.